Watchful waiting and factors predictive of secondary treatment of localized prostate cancer

Hongyan Wu, Leon Sun, Judd W. Moul, Hongyu Wu, David G. McLeod, Christopher Amling, Raymond Lance, Leo Kusuda, Timothy Donahue, John Foley, Andrew Chung, Wade Sexton, Douglas Soderdahl

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Watchful waiting remains an important treatment option for some patients with localized prostate cancer. We defined the demographic, clinical and outcome features of men selecting watchful waiting as an initial treatment strategy, and determined factors predictive of eventual progression to secondary treatment. Materials and Methods: Of 8,390 patients diagnosed with prostate cancer from 1990 to 2001 in the Department of Defense Center for Prostate Disease Research Database, 1,158 patients chose watchful waiting as initial treatment. The demographic and clinical differences between patients on watchful waiting and those choosing other initial treatments were compared using the chi-square test. Secondary treatment-free survival according to various prognostic factors was plotted using the Kaplan-Meier method and differences were tested using the log rank test. A multivariate Cox proportional hazards regression analysis was performed to determine which factors were independent predictors of secondary treatment. Results: Compared to other patients, those selecting watchful waiting were older, had lower prostate specific antigen (PSA) at diagnosis, and were more likely to have lower stage (cT1) and lower grade (Gleason sum 7 or less) cancers. Age, PSA and clinical stage were all significant and independent predictors of secondary treatment. The relative risk of secondary treatment can be expressed as EXP (-0.034 × age at diagnosis + 0.284 × LOG (diagnostic PSA) + 0.271 × clinical stage T2 + 0.264 × clinical stage T3). Conclusions: Men who elect watchful waiting as initial management for prostate cancer are older with lower Gleason sums and serum PSA. In these men, age at diagnosis, serum PSA and clinical stage are the most significant predictors of requiring or selecting secondary treatment.

Original languageEnglish (US)
Pages (from-to)1111-1116
Number of pages6
JournalJournal of Urology
Volume171
Issue number3
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Watchful Waiting
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Demography
Chi-Square Distribution
Serum
Prostate
Regression Analysis
Databases

Keywords

  • Prognosis
  • Prostate-specific antigen
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. / Wu, Hongyan; Sun, Leon; Moul, Judd W.; Wu, Hongyu; McLeod, David G.; Amling, Christopher; Lance, Raymond; Kusuda, Leo; Donahue, Timothy; Foley, John; Chung, Andrew; Sexton, Wade; Soderdahl, Douglas.

In: Journal of Urology, Vol. 171, No. 3, 03.2004, p. 1111-1116.

Research output: Contribution to journalArticle

Wu, H, Sun, L, Moul, JW, Wu, H, McLeod, DG, Amling, C, Lance, R, Kusuda, L, Donahue, T, Foley, J, Chung, A, Sexton, W & Soderdahl, D 2004, 'Watchful waiting and factors predictive of secondary treatment of localized prostate cancer', Journal of Urology, vol. 171, no. 3, pp. 1111-1116. https://doi.org/10.1097/01.ju.0000113300.74132.8b
Wu, Hongyan ; Sun, Leon ; Moul, Judd W. ; Wu, Hongyu ; McLeod, David G. ; Amling, Christopher ; Lance, Raymond ; Kusuda, Leo ; Donahue, Timothy ; Foley, John ; Chung, Andrew ; Sexton, Wade ; Soderdahl, Douglas. / Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. In: Journal of Urology. 2004 ; Vol. 171, No. 3. pp. 1111-1116.
@article{916c1cea58b549bfb8c36b2064936a4b,
title = "Watchful waiting and factors predictive of secondary treatment of localized prostate cancer",
abstract = "Purpose: Watchful waiting remains an important treatment option for some patients with localized prostate cancer. We defined the demographic, clinical and outcome features of men selecting watchful waiting as an initial treatment strategy, and determined factors predictive of eventual progression to secondary treatment. Materials and Methods: Of 8,390 patients diagnosed with prostate cancer from 1990 to 2001 in the Department of Defense Center for Prostate Disease Research Database, 1,158 patients chose watchful waiting as initial treatment. The demographic and clinical differences between patients on watchful waiting and those choosing other initial treatments were compared using the chi-square test. Secondary treatment-free survival according to various prognostic factors was plotted using the Kaplan-Meier method and differences were tested using the log rank test. A multivariate Cox proportional hazards regression analysis was performed to determine which factors were independent predictors of secondary treatment. Results: Compared to other patients, those selecting watchful waiting were older, had lower prostate specific antigen (PSA) at diagnosis, and were more likely to have lower stage (cT1) and lower grade (Gleason sum 7 or less) cancers. Age, PSA and clinical stage were all significant and independent predictors of secondary treatment. The relative risk of secondary treatment can be expressed as EXP (-0.034 × age at diagnosis + 0.284 × LOG (diagnostic PSA) + 0.271 × clinical stage T2 + 0.264 × clinical stage T3). Conclusions: Men who elect watchful waiting as initial management for prostate cancer are older with lower Gleason sums and serum PSA. In these men, age at diagnosis, serum PSA and clinical stage are the most significant predictors of requiring or selecting secondary treatment.",
keywords = "Prognosis, Prostate-specific antigen, Prostatic neoplasms",
author = "Hongyan Wu and Leon Sun and Moul, {Judd W.} and Hongyu Wu and McLeod, {David G.} and Christopher Amling and Raymond Lance and Leo Kusuda and Timothy Donahue and John Foley and Andrew Chung and Wade Sexton and Douglas Soderdahl",
year = "2004",
month = "3",
doi = "10.1097/01.ju.0000113300.74132.8b",
language = "English (US)",
volume = "171",
pages = "1111--1116",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Watchful waiting and factors predictive of secondary treatment of localized prostate cancer

AU - Wu, Hongyan

AU - Sun, Leon

AU - Moul, Judd W.

AU - Wu, Hongyu

AU - McLeod, David G.

AU - Amling, Christopher

AU - Lance, Raymond

AU - Kusuda, Leo

AU - Donahue, Timothy

AU - Foley, John

AU - Chung, Andrew

AU - Sexton, Wade

AU - Soderdahl, Douglas

PY - 2004/3

Y1 - 2004/3

N2 - Purpose: Watchful waiting remains an important treatment option for some patients with localized prostate cancer. We defined the demographic, clinical and outcome features of men selecting watchful waiting as an initial treatment strategy, and determined factors predictive of eventual progression to secondary treatment. Materials and Methods: Of 8,390 patients diagnosed with prostate cancer from 1990 to 2001 in the Department of Defense Center for Prostate Disease Research Database, 1,158 patients chose watchful waiting as initial treatment. The demographic and clinical differences between patients on watchful waiting and those choosing other initial treatments were compared using the chi-square test. Secondary treatment-free survival according to various prognostic factors was plotted using the Kaplan-Meier method and differences were tested using the log rank test. A multivariate Cox proportional hazards regression analysis was performed to determine which factors were independent predictors of secondary treatment. Results: Compared to other patients, those selecting watchful waiting were older, had lower prostate specific antigen (PSA) at diagnosis, and were more likely to have lower stage (cT1) and lower grade (Gleason sum 7 or less) cancers. Age, PSA and clinical stage were all significant and independent predictors of secondary treatment. The relative risk of secondary treatment can be expressed as EXP (-0.034 × age at diagnosis + 0.284 × LOG (diagnostic PSA) + 0.271 × clinical stage T2 + 0.264 × clinical stage T3). Conclusions: Men who elect watchful waiting as initial management for prostate cancer are older with lower Gleason sums and serum PSA. In these men, age at diagnosis, serum PSA and clinical stage are the most significant predictors of requiring or selecting secondary treatment.

AB - Purpose: Watchful waiting remains an important treatment option for some patients with localized prostate cancer. We defined the demographic, clinical and outcome features of men selecting watchful waiting as an initial treatment strategy, and determined factors predictive of eventual progression to secondary treatment. Materials and Methods: Of 8,390 patients diagnosed with prostate cancer from 1990 to 2001 in the Department of Defense Center for Prostate Disease Research Database, 1,158 patients chose watchful waiting as initial treatment. The demographic and clinical differences between patients on watchful waiting and those choosing other initial treatments were compared using the chi-square test. Secondary treatment-free survival according to various prognostic factors was plotted using the Kaplan-Meier method and differences were tested using the log rank test. A multivariate Cox proportional hazards regression analysis was performed to determine which factors were independent predictors of secondary treatment. Results: Compared to other patients, those selecting watchful waiting were older, had lower prostate specific antigen (PSA) at diagnosis, and were more likely to have lower stage (cT1) and lower grade (Gleason sum 7 or less) cancers. Age, PSA and clinical stage were all significant and independent predictors of secondary treatment. The relative risk of secondary treatment can be expressed as EXP (-0.034 × age at diagnosis + 0.284 × LOG (diagnostic PSA) + 0.271 × clinical stage T2 + 0.264 × clinical stage T3). Conclusions: Men who elect watchful waiting as initial management for prostate cancer are older with lower Gleason sums and serum PSA. In these men, age at diagnosis, serum PSA and clinical stage are the most significant predictors of requiring or selecting secondary treatment.

KW - Prognosis

KW - Prostate-specific antigen

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=12144289009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144289009&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000113300.74132.8b

DO - 10.1097/01.ju.0000113300.74132.8b

M3 - Article

C2 - 14767282

AN - SCOPUS:12144289009

VL - 171

SP - 1111

EP - 1116

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -